Value-Based Strategies for Reimbursement and Formulary Success

Develop a drug value composition that illustrates minimized costs and maximized health outcomes to prove your product deserves formulary access.

November 6-7, 2017 \ Hyatt Regency Bethesda \ Bethesda, MD

FEATURED SESSIONS

**PFIZER**

What Is Right and What Is Wrong With Prescription Drug Pricing, Cost and Affordability?

Robert Popovian, Pharm.D.,
Vice President, U.S. Government Relations

**BRAEBURN PHARMACEUTICALS**

Navigate Unchartered Waters With Value-Based Purchasing for Manufacturers

David Byram,
Vice President, Market Access and Government Affairs

**JOHNSON & JOHNSON**

Gain New Understanding of the Role of Real-World Data in Value-Based Payments

Natalie Heidrich,
Director, Field Health Economics Market Access

**CASTLE CREEK PHARMACEUTICALS**

Inspect the Payer Spider Web to Determine How to Dissect, Evaluate, and Develop a Comprehensive Strategy

Greg Wujek,
Vice President, Market Access

**MERCK & CO.**

Case Study: Merck’s Collaboration With Optum to Advance Value-Based Contracting

Wanmei Ou, Ph.D.,
Director, Precision Medicine & Data Science, Center for Observational and Real-World Evidence

BRAND-NEW SESSIONS ILLUSTRATE HOW TO:

- Navigate policies specific to the four reimbursement categories
- Develop value-based arrangements with payers to gain formulary access and increase market share
- Cultivate mitigation strategies for formulary restriction
- Leverage real-world data to create and demonstrate product value

The ONLY educational event specifically devoted to this timely content!

- Develop a value proposition that satisfies cost-benefit analysis
- Identify compliant tactics to engage payers during pre-FDA approval
- Network with top experts in value-based arrangements and gaining formulary access
Dear Colleague,

Proving value in the context of price is critical to the success, marketing, and differentiation of a product. Within organizations, regulatory, commercial, R&D, and market access teams are challenged to collaboratively develop a narrative that proves a product’s efficacy through clinical, regulatory, and commercial benchmark markers. If initially rejected from the formulary, life science organizations are then faced with developing innovative strategies to get a product in front of the right patients, utilize the resulting real-world evidence, and then return to the payer with greater proof of the drug’s efficacy and increased value.

By pioneering the conversation of the transition from price-centric to value-based formularies, life science and healthcare insurance executives will provide attendees with education in proving value, instead of managing pricing, of drugs coming onto the market. This event will arm professionals with the skills and methods to prepare for formulary success before FDA approval through regulatory, medical affairs, R&D, and market access collaboration. The event will also provide strategies for those who do not gain formulary access initially so that attendees also walk away with an auxiliary strategy to ultimately gain formulary approval through post-approval market access expansion tactics using real-world evidence and HEOR.

The Value-Based Strategies for Reimbursement and Formulary Success will explore shared challenges including:

- How to navigate the future of healthcare reimbursement given today’s healthcare climate
- Creating proactive strategies that expand patient access in an era of increasing cost controls and utilization management
- Selecting the data and metrics per therapeutic type necessary to prove a product’s value
- How to use real-world evidence to verify a drug’s increased value post-approval
- Proving that a drug is not only valuable for its therapeutic outcomes, but for overall decreases in healthcare costs

I look forward to welcoming you to Bethesda this fall!

Sincerely,

Mercy Lister

Mercy Lister
Conference Director
ExL Events, A Division of Questex

WHO SHOULD ATTEND

This conference is designed for representatives from pharmaceutical, medical device, biotechnology and payers with responsibilities in the following areas:

- Formulary Management/Operations
- Reimbursement
- Health Economics & Outcomes Research
- Value-Based Care
- Market Access
- Contracting
- Pricing
- Managed Markets
- Payer Strategy
- National Accounts
- Managed Care
- Indication-Specific Pricing
- Patient-Centered Outcomes

This conference is also of interest to:

- HEOR Solution Providers
- Real-World Evidence Service Providers
- Pricing Solution Providers
- Contracting Vendors
- Market Access Vendors
- Reimbursement Solution Providers
- Formulary Access Vendors

VENUE

HYATT REGENCY BETHESDA
1 Bethesda Metro Center  Bethesda, MD 20814

To make reservations, please call 1-888-421-1442 and request the negotiated rate for ExL’s November Meetings. You may also make reservations online using the following weblink: http://bit.ly/2s8dwYW. Please book your room early, as rooms available at this rate are limited.

*ExL Events is not affiliated with Exhibition Housing Management (EHM)/Exhibitors Housing Services (EHS) or any third-party booking agencies, housing bureaus or travel companies. ExL Events is affiliated with event company Questex, LLC. in the event that an outside party contacts you for any type of hotel or travel arrangements, please disregard these solicitations and kindly email us at info@exlevents.com. ExL has not authorized these companies to contact you and we do not verify the legitimacy of the services or rates offered. Please book your guest rooms through ExL’s reserved guest room block using the details provided.

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

Do you want to spread the word about your organization’s solutions and services to potential clients attending this event? Take advantage of the opportunity to exhibit, underwrite an educational session, host a networking event or distribute promotional items to attendees. ExL Events will work closely with you to customize a package that will suit all of your needs. To learn more about these opportunities, please contact us at 201 871 0474 or register@pmaconference.com.
8:00 Registration and Continental Breakfast
9:00 Chairperson’s Opening Remarks

EXAMINING THE VALUE-BASED HEALTHCARE LANDSCAPE

9:15 Examine What Is Right and What Is Wrong With Prescription Drug Pricing, Cost and Affordability in the United States
• Learn how medicines today are divided into four categories, each category requiring specific policies to address the pricing, cost and affordability challenges
• Understand that medicines are the most valuable intervention in healthcare, more than physicians, hospitals and pharmacists, and question how society can get the most value from the most valuable intervention
• Examine why we need a more transparent financing system in the U.S.
Robert Popovian, Pharm.D., Vice President, U.S. Government Relations, PFIZER

10:00 Leverage Internal and External Collaboration to Position Your Product/Procedure in a Value Based Healthcare Environment
• Use the marketplace and product/procedure attributes to develop a value-based positioning approach
• Gain strong product positioning through a value-based healthcare and population health lens
• Collaborate with internal and external stakeholders to success
Natalie Heidrich, Director, Field Health Economics Market Access, JOHNSON & JOHNSON MEDICAL DEVICE COMPANIES

10:45 Networking Break

DEVELOPING VALUE-PROPOSITIONS

11:15 Tailor Value Propositions to Meet an Institution’s Needs, One Question at a Time
• Better understand the fundamental construct of a “tailor-made” value proposition
• Discuss your story and the sense of urgency behind developing an effective approach
• Identify key components in the process behind developing an appropriate value proposition
• Illustrate pitfalls, assumptions and common mistakes in value application metrics
• Review a case study from failure to success: a product’s story of institutional redemption
Aaron Shaw, RN-BSN, Medical Director, Medical Science Liaison Team, PACIRA PHARMACEUTICALS

12:00 Develop Value Propositions to Reflect Patient Needs
• Develop elements of value by placing the patient’s voice at the center of the value equation
• Debate how to quantify qualitative patient data to prove product efficacy
• Question how to leverage technology to capture data that fits requirements and expands upon access issues

VALUE-BASED CONTRACTING

1:45 Navigate Uncharted Waters With Value-Based Purchasing for Manufacturers
• Set the stage in advance of value-based purchasing agreements
• Define the metrics of a good value-based purchase
• Examine common pitfalls to avoid in negotiating value-based purchasing agreements
David Byram, Vice President, Market Access and Government Affairs, BRAEBURN PHARMACEUTICALS

2:30 Review Best Practices in Value-Based Contracting for Pharmaceuticals
• Systematically study critical factors for successful implementation of value-based contracts
• Design value-based contracts to reduce clinical and financial uncertainty
• Use real-world data to develop and test advanced predictive models in order to evaluate value-based contracts
Wanmei Ou, Ph.D., Director, Precision Medicine & Data Science, Center for Observational and Real-World Evidence, MERCK & CO.

3:15 Networking Break

3:45 Gain New Understanding of the Role of Real-World Data in Value-Based Payments
• Gain new comprehension of how changes in the U.S. landscape are affecting stakeholder priorities
• Dissect the growing and future role of real-world evidence in decision making under value-based payments
• Learn about U.S. trends in determining the value of medicines, and ways pharma can leverage real-world data to create and demonstrate value
Melinda Hanisch, Director, Research Dissemination, Center for Observational and Real-World Evidence, MERCK & CO.

4:30 Best Practices in Early Market Access Strategy Development
• Review brand development and commercialization strategies that increase market access
• Consider payer engagement opportunities available in early stages
• Identify tactics that develop value narrative and open access
Rob Laverty, Vice President, Market Access, OTSUKA PHARMACEUTICAL COMPANIES

5:15 Day One Concludes
8:00 Registration and Continental Breakfast
9:00 Chairperson's Recap of Day One

ALIGNING WITH PAYERS

9:15 Inspect the Payer Spider Web to Determine How to Dissect, Evaluate, and Develop a Comprehensive Strategy
- Examine when payer engagement should begin
- Review the relevant information for a value proposition, dependent upon product/therapeutic type
- Debate if value-based contracting is feasible for your product
- Consider key variables for a cost-benefit analysis
- Define the importance of your distribution model and supporting programs
- Understand the worst-case formulary position scenario and how to best address it

Greg Wujek, Vice President, Market Access, CASTLE CREEK PHARMACEUTICALS

10:00 Establish Early Payer Strategies for Rare Disease Products
- Develop an understanding of payer challenges with respect to rare diseases
- Capture and integrate the patient journey to develop a multi-phased engagement strategy

Raquel Cabo, Vice President, Global Market Access, OVID THERAPEUTICS

10:45 Networking Break

11:15 Develop Evidence for Pharma-Payer Partnerships
- Create a multichannel approach to improving adherence
- Consider benefits and services available beyond the pill
- Improve favorable positioning in the market through payer partnerships

Jesse Fishman, Scientific and Real-World Data Alliances Lead Neurology Patient Value Unit, U.S. Medical Affairs, UCB

12:00 Strategically Align Goals and Objectives With Payers to Optimize Value-Based Arrangements
- Develop a win/win proposition that furthers patient care, increases access to appropriate medications, and meets payer and manufacturer goals
- Review lessons learned from successfully executed value-based arrangements
- Review the biggest issues of value-based arrangements and proven successful mitigation strategies for the common issues

Gina Guinasso, J.D., Senior Director, Market Access, TAKEDA
Greg Wujek, Vice President, Market Access, CASTLE CREEK PHARMACEUTICALS
Jesse Fishman, Scientific and Real-World Data Alliances Lead Neurology Patient Value Unit, U.S. Medical Affairs, UCB
Aaron Shaw, RN-BSN, Medical Director, Medical Science Liaison Team, PACIRA PHARMACEUTICALS

Tuesday, November 7, 2017

EXPANDING MARKET ACCESS

1:45 Define Strategies to Ensure Market Access for Vulnerable Populations
- Compare different payer access tactics dependent upon beneficiary type
- Drive value for members by expanding benefits over costs
- Knock down barriers (i.e. cost) to ensure the right member gets the right product at the right time

Timothy Mizak, Pharm.D., Manager, Clinical Operations and Value-Based Purchasing, GATEWAY HEALTH PLAN

2:30 Explore Day-to-Day Access Barriers at Various Levels That Impact the Time From Prescribed to On-Therapy
- Identify challenges to patient access with the introduction of less-expensive biosimilars
- Consider real-world suggestions to streamline and optimize patient access while developing a proactive strategy for customer engagement
- Address the successes and rewards of advocating for those who are at their weakest

Melissa L. Paige, Oncology Patient Access Principal Coordinator, UNIVERSITY OF VIRGINIA HEALTH SYSTEM, NCI-DESIGNATED EMMILY COURIC CLINICAL CANCER CENTER

3:15 Chairperson’s Closing Remarks
3:45 Conference Concludes

METHODOLOGY TO EXPAND ACCESS

- Collaborate with patients, payers and providers to deliver greater value
- Leverage real-world data to create and demonstrate value
- Develop value propositions that are specific to therapeutic type and institution needs

- Define your product and targeted patient population to narrow market access efforts
- Replace traditional pricing models with outcomes-based reimbursement

METHODOLOGY TO CONTROL COSTS

- Develop a win/win proposition that furthers patient care, increases access to appropriate medications, and meets payer and manufacturer goals
- Review lessons learned from successfully executed value-based arrangements
- Review the biggest issues of value-based arrangements and proven successful mitigation strategies for the common issues

Gina Guinasso, J.D., Senior Director, Market Access, TAKEDA
Greg Wujek, Vice President, Market Access, CASTLE CREEK PHARMACEUTICALS
Jesse Fishman, Scientific and Real-World Data Alliances Lead Neurology Patient Value Unit, U.S. Medical Affairs, UCB
Aaron Shaw, RN-BSN, Medical Director, Medical Science Liaison Team, PACIRA PHARMACEUTICALS
Media Partners

Group Discount Program

Save 25% per person when registering four
For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register four at one time). This is a savings of 25% per person.

Save 15% per person when registering three
Can only send three? You can still save 15% off every registration. Offers may not be combined. Early bird rates do not apply. To find out more about how you can take advantage of these group discounts, please call 201 871 0474.

TERMS AND CONDITIONS: By registering for an ExL Events ("ExL") event, you agree to the following set of terms and conditions listed below:

REGISTRATION FEE: The fee includes the conference, all program materials, and designated continental breakfasts, lunches and refreshments.

PAYMENT: Make checks payable to ExL Events and write C921 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options.

**Please Note: There will be an administrative charge of $300 to substitute, exchange and/or replace attendance badges with a colleague within five business days of any ExL conference.**

CANCELLATION AND REFUND POLICY: If you cancel your registration for an upcoming ExL event, the following policies apply, derived from the Start Date of the event:

- Four weeks or more: A full refund (minus a $295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date.
- Less than four weeks: A voucher to another ExL event valid for 12 months from the voucher issue date.
- Five days or less: A voucher (minus a $395 processing and documentation fee) to another ExL event valid for 12 months from the voucher issue date.

CREDIT VOUCHERS: Credit vouchers are valid for 12 months from date of issue. Credit vouchers are valid toward one (1) ExL event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is not applicable now or in the future. Once a credit voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees’ behalf, the credit voucher will no longer be valid.

ExL Events does not and is not obligated to provide a credit voucher to registered attendee(s) who do not attend the event they registered for unless written notice of intent to cancel is received and confirmed prior to the commencement of the event.

SUBSTITUTION CHARGES: There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare, hotel or any other expenses incurred by registrants.

ExL Events’ liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date, content, speakers and/or venue.

*The opinions of ExL's conference speakers do not necessarily reflect those of the companies they represent, nor ExL Events. Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL's designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redistribution to other outlets without the express written permission of ExL's designated speaking parties. Neither ExL nor its content providers and/or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. EXL EVENTS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of, or endorse the views or opinions given by any third party content provider. ExL presentations may point to other websites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites.
Value-Based Strategies for Reimbursement and Formulary Success

Develop a drug value composition that illustrates minimized costs and maximized health outcomes to prove your product deserves formulary access.

November 6-7, 2017 \ Hyatt Regency Bethesda \ Bethesda, MD

FEATURED SPEAKERS

**PFIZER**
- Robert Popovian, Pharm.D., Vice President, U.S. Government Relations

**BRAEBURN PHARMACEUTICALS**
- David Byram, Vice President, Market Access and Government Affairs

**JOHNSON & JOHNSON**
- Natalie Heidrich, Director, Field Health Economics Market Access

**CASTLE CREEK PHARMACEUTICALS**
- Greg Wujek, Vice President, Market Access

**MERCK & CO.**
- Wanmei Ou, Ph.D., Director, Precision Medicine & Data Science, Center for Observational and Real-World Evidence